Merck (MRK)

85.36 +0.87 (1.03%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/26/19 *Est.)
- M&A (6/30/19 *Est)
- Investor Day (6/20/2019)

Latest Headlines

Merck (MRK) June option implied volatility bid on more calls than puts into investor day June 19, 2019 3:51 PM - StreetInsider Merck (MRK) Gains Into Tomorrow's Investor Day June 19, 2019 3:48 PM - StreetInsider Merck (MRK) June calls stay active into investor day June 19, 2019 10:47 AM - StreetInsider AstraZeneca (AZN) and Merck's LYNPARZA Approved in Japan as First-Line Maintenance Therapy in Patients with BRCAm Advanced Ovarian Cancer June 19, 2019 6:48 AM - StreetInsider AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer June 19, 2019 6:45 AM - BizWire Merck (MRK) Seeks Small and Midsize Deals - DJ June 19, 2019 6:21 AM - StreetInsider Merck (MRK) call active into investor day June 19, 2019 5:29 AM - StreetInsider Merck (MRK) June 84 calls active into investor day June 18, 2019 2:07 PM - StreetInsider Merck (MRK) Announces FDA Approved its KEYTRUDA as Monotherapy for Some Patients with Metastatic SCLC with Disease Progression June 18, 2019 6:47 AM - StreetInsider FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Leas June 18, 2019 6:45 AM - BizWire AstraZeneca (AZN), Merck (MRK) Announce EC Approval of Lynparza for Ovarian Cancer June 18, 2019 6:31 AM - StreetInsider LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer June 18, 2019 6:30 AM - BizWire IBM (IBM), Merck (MRK), Walmart (WMT), KPMG to Collaborate with FDA on Pharma Product Integrity Protection Using Blockchain June 13, 2019 8:14 AM - StreetInsider IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the use of blockchain to protect pharmaceutical product integrity June 13, 2019 8:05 AM - PR NewsWire Merck (MRK) Announces FDA Approved Two New Indications for KEYTRUDA June 11, 2019 6:46 AM - StreetInsider FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab) June 11, 2019 6:45 AM - BizWire Merck (MRK) to Acquire Tilos Therapeutics for up to $773 Million June 10, 2019 6:45 AM - StreetInsider Merck to Acquire Tilos Therapeutics June 10, 2019 6:45 AM - BizWire Form 4 Merck & Co., Inc. For: May 31 Filed by: WEEKS WENDELL P June 4, 2019 5:22 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: THULIN INGE G June 4, 2019 5:21 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: RUSSO PATRICIA F June 4, 2019 5:21 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: WENDELL PETER C June 4, 2019 5:21 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: LAZARUS ROCHELLE B June 4, 2019 5:20 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: Rothman Paul June 4, 2019 5:20 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: Craig Pamela J. June 4, 2019 5:20 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: GLOCER THOMAS H June 4, 2019 5:20 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: Cech Thomas R June 4, 2019 5:19 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: BRUN LESLIE A June 4, 2019 5:19 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 31 Filed by: Coe Mary Ellen June 4, 2019 5:18 PM - SEC Filing Merck (MRK) Confirms FDA Approved its ZERBAXA 3g Dose for Treatment of Adults with HABP/VABP June 3, 2019 4:57 PM - StreetInsider FDA Approves Merck’s ZERBAXA® (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) June 3, 2019 4:55 PM - BizWire Merck's (MRK) LYNPARZA Phase 3 SOLO3 Trial Demonstrated 72% OR Rate in Patients with Platinum-Sensitive Relapsed gBRCAm June 3, 2019 4:19 PM - StreetInsider LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patie June 3, 2019 4:15 PM - BizWire FDA approves Merck's (MRK) new treatment for hospital-acquired and ventilator-associated bacterial pneumonia June 3, 2019 3:31 PM - StreetInsider Merck KGaA, Darmstadt, Germany Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations June 3, 2019 10:25 AM - PR NewsWire Merck (MRK), AstraZeneca (AZN) Report Results from Phase 3 POLO trial evaluating LYNPARZA as First-Line Maintenance Therapy June 3, 2019 6:04 AM - StreetInsider LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Ca June 2, 2019 7:30 AM - BizWire Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting June 1, 2019 7:30 AM - BizWire Form 8-K Merck & Co., Inc. For: May 31 May 31, 2019 10:56 AM - SEC Filing Merck's (MRK) KEYTRUDA (pembrolizumab) Demonstrates Improved OS at Final Analysis of Pivotal Phase 3 KEYNOTE-048 Trial May 31, 2019 6:48 AM - StreetInsider Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Improved Overall Survival as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at Final Analysis of Pivotal Phase May 31, 2019 6:45 AM - BizWire EMD Serono Makes Multiple Sclerosis Visible This World MS Day and Beyond May 30, 2019 9:02 AM - PR NewsWire Merck (MRK) Declares $0.55 Quarterly Dividend; 2.7% Yield May 28, 2019 4:09 PM - StreetInsider Merck Announces Third-Quarter 2019 Dividend May 28, 2019 4:05 PM - BizWire EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients May 28, 2019 1:53 PM - PR NewsWire Goldman Sachs Starts Merck (MRK) at Neutral May 28, 2019 2:43 AM - StreetInsider Form SD Merck & Co., Inc. May 23, 2019 10:44 AM - SEC Filing Merck Foundation Announces Grant to American Cancer Society to Improve Access to Cancer Care in Resource-Limited Settings May 22, 2019 8:00 AM - BizWire Merck (MRK) to Acquire Peloton Therapeutics for $1.05 Billion Upfront, Plus $1.15 Billion Contingent May 21, 2019 6:45 AM - StreetInsider Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline May 21, 2019 6:45 AM - BizWire Merck (MRK) Phase 3 KEYNOTE-119 Study of KEYTRUDA Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer Doesn't Meet Primary Endpoint May 20, 2019 4:32 PM - StreetInsider Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer May 20, 2019 4:30 PM - BizWire Supreme Court Sends Merck's (MRK) Fosamax Case Back to Lower Court - Bloomberg May 20, 2019 10:13 AM - StreetInsider MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing May 20, 2019 8:00 AM - PR NewsWire Pre-Open Movers 05/16: (OTLK) (IOVA) (MRTX) Higher; (VRTU) (ADMA) (PLYM) (more...) May 16, 2019 9:27 AM - StreetInsider Intec Pharma (NTEC), Merck (MRK) Announce Research Collaboration Agreement to Explore Accordion Pill Platform for Development May 16, 2019 6:06 AM - StreetInsider Third Point's 13F shows new stakes in Boston Scientific (BSX), Celgene (CELG), NetFlix (NFLX) (more...) May 15, 2019 5:17 PM - StreetInsider New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting May 15, 2019 5:00 PM - BizWire FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma May 14, 2019 7:44 PM - PR NewsWire Form 4 Merck & Co., Inc. For: May 10 Filed by: Karachun Rita A May 13, 2019 5:07 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 10 Filed by: Nally Michael May 13, 2019 5:07 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 10 Filed by: Fleming Michael May 13, 2019 5:07 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 10 Filed by: Clyburn Frank May 13, 2019 5:06 PM - SEC Filing Atlantic Equities Upgrades Merck (MRK) to Overweight May 13, 2019 5:27 AM - StreetInsider Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS May 10, 2019 1:46 PM - PR NewsWire Form 4 Merck & Co., Inc. For: May 06 Filed by: FRAZIER KENNETH C May 9, 2019 6:12 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 07 Filed by: Clyburn Frank May 9, 2019 6:12 PM - SEC Filing Katie Couric Joins Merck and Cancer Advocates to Support Patients and Caregivers Through the Expansion of Your Cancer Game Plan (YCGP) May 9, 2019 7:00 AM - BizWire Form 10-Q Merck & Co., Inc. For: Mar 31 May 8, 2019 4:39 PM - SEC Filing Merck (MRK) Reports Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants May 8, 2019 9:01 AM - StreetInsider Merck Announces Results from Phase 2 Trial of Investigational 15-valent Pneumococcal Conjugate Vaccine (V114) in Infants May 8, 2019 9:00 AM - BizWire Form 4 Merck & Co., Inc. For: May 03 Filed by: DeLuca Richard R. May 7, 2019 8:34 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Fleming Michael May 7, 2019 8:33 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Karachun Rita A May 7, 2019 8:33 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Zachary Jennifer May 7, 2019 7:42 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Scholefield James H May 7, 2019 7:42 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: PERLMUTTER ROGER M May 7, 2019 7:42 PM - SEC Filing Form 3/A Merck & Co., Inc. For: Jan 01 Filed by: Nally Michael May 7, 2019 7:41 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Nally Michael May 7, 2019 7:41 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: MIZELL STEVEN May 7, 2019 7:40 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Gerberding Julie L. May 7, 2019 7:40 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: FRAZIER KENNETH C May 7, 2019 7:39 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Davis Robert M May 7, 2019 7:39 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Clyburn Frank May 7, 2019 7:38 PM - SEC Filing Form 4 Merck & Co., Inc. For: May 03 Filed by: Chattopadhyay Sanat May 7, 2019 7:38 PM - SEC Filing EMD Serono Launches MS-LINK™, a Community to Advance MS Science and Improve Patient Lives May 7, 2019 8:00 AM - PR NewsWire Merck's (MRK) BELSOMRA C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia May 7, 2019 6:46 AM - StreetInsider Merck’s BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia May 7, 2019 6:45 AM - BizWire Merck (MRK) PT Lowered to $87 at UBS May 2, 2019 7:58 AM - StreetInsider Form PX14A6G Merck & Co., Inc. Filed by: Oxfam America, Inc. May 1, 2019 4:18 PM - SEC Filing Merck (MRK) PT Raised to $91 at Wolfe Research May 1, 2019 8:44 AM - StreetInsider Merck (MRK) PT Raised to $84 at Morgan Stanley May 1, 2019 8:13 AM - StreetInsider Merck (MRK) PT Raised to $84 at BMO Capital May 1, 2019 7:50 AM - StreetInsider Merck (MRK) PT Raised to $91 at BofA/Merrill Lynch May 1, 2019 6:53 AM - StreetInsider EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019 April 30, 2019 8:08 AM - PR NewsWire Form 8-K Merck & Co., Inc. For: Apr 30 April 30, 2019 6:50 AM - SEC Filing Merck (MRK) Tops Q1 EPS by 17c, Updates FY Guidance April 30, 2019 6:47 AM - StreetInsider Merck Announces First-Quarter 2019 Financial Results April 30, 2019 6:45 AM - BizWire Merck (MRK) Announces LYNPARZA Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cance April 29, 2019 6:45 AM - StreetInsider LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer April 29, 2019 6:45 AM - BizWire Merck (MRK) PT Lowered to $87 at UBS April 26, 2019 7:20 AM - StreetInsider Merck (MRK) Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA Met Primary Endpoint, Was not Found to be Superior for OS April 25, 2019 5:20 PM - StreetInsider Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric April 25, 2019 5:19 PM - BizWire Merck and Viola Davis to Debut A Touch of Sugar During Tribeca Film Festival® April 25, 2019 8:00 AM - PR NewsWire BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston April 23, 2019 6:30 AM - Globe NewsWire Form PX14A6G Merck & Co., Inc. Filed by: Seventh Generation Interfaith Inc. April 22, 2019 5:12 PM - SEC Filing Merck (MRK) Reports FDA Approval of KEYTRUDA (pembrolizumab) in Combination With Inlyta®= (axitinib) April 22, 2019 6:46 AM - StreetInsider FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC) April 22, 2019 6:45 AM - BizWire Merck (MRK), Lilly (LLY), Pfizer (PFE) Weakness Continues as Biotech Shares Get Hit Again April 18, 2019 10:23 AM - StreetInsider Merck (MRK), Pfizer (PFE) Lilly (LLY) Shares Decline Amid Biotech Weakness April 17, 2019 10:26 AM - StreetInsider Merck (MRK) option implied volatility flat as shares near record high April 16, 2019 10:19 AM - StreetInsider Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCM April 13, 2019 7:00 AM - BizWire Merck (MRK) Announces FDA Approval of Expanded Monotherapy Label for its KEYTRUDA April 11, 2019 5:45 PM - StreetInsider FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab) April 11, 2019 5:45 PM - BizWire AstraZeneca (AZN) and Merck's (MRK) LYNPARZA Approved in EU for Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer April 10, 2019 6:46 AM - StreetInsider LYNPARZA® (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer April 10, 2019 6:45 AM - BizWire Form DEFA14A Merck & Co., Inc. April 8, 2019 5:10 PM - SEC Filing Form DEFA14A Merck & Co., Inc. April 8, 2019 5:07 PM - SEC Filing Form DEF 14A Merck & Co., Inc. For: May 28 April 8, 2019 5:03 PM - SEC Filing MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts April 8, 2019 2:03 PM - PR NewsWire Myriad Genetics (MYGN), AstraZeneca (AZN) and Merck (MRK) Expand Companion Diagnostic Partnership April 4, 2019 7:08 AM - StreetInsider Merck (MRK) option implied volatility is low April 3, 2019 11:02 AM - StreetInsider BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity April 3, 2019 8:30 AM - Globe NewsWire Form 4 Merck & Co., Inc. For: Mar 29 Filed by: WEEKS WENDELL P April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: WENDELL PETER C April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: Coe Mary Ellen April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: GLOCER THOMAS H April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: Noseworthy John H April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: LAZARUS ROCHELLE B April 2, 2019 5:06 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 29 Filed by: THULIN INGE G April 2, 2019 5:06 PM - SEC Filing BriaCell Announces Clinical Trial Collaboration Agreement with Incyte April 2, 2019 2:58 PM - Globe NewsWire Merck (MRK) Completes Tender Offer to Acquire Immune Design (IMDZ) April 2, 2019 6:46 AM - StreetInsider Merck Completes Tender Offer to Acquire Immune Design April 2, 2019 6:45 AM - BizWire Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30 April 2, 2019 6:30 AM - BizWire BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million April 1, 2019 6:45 PM - Globe NewsWire Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals April 1, 2019 4:45 PM - BizWire Merck (MRK) Reports Data for KEYTRUDA (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR 2019 April 1, 2019 8:34 AM - StreetInsider Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019 April 1, 2019 8:30 AM - BizWire Cantor Fitzgerald Reiterates Overweight Rating On Merck (MRK) On Keytruda Chinese Conditional Approval April 1, 2019 8:17 AM - StreetInsider Merck's (MRK) KEYTRUDA Approved in China for First-Line Treatment of Metastatic Nonsquamous NSCLC in Combination with Chemotherapy April 1, 2019 6:55 AM - StreetInsider Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy April 1, 2019 6:55 AM - BizWire AstraZeneca (AZN) and Merck (MRK) Announce Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1 April 1, 2019 6:34 AM - StreetInsider Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1 April 1, 2019 6:30 AM - BizWire FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis March 29, 2019 7:55 PM - PR NewsWire Form 3 Merck & Co., Inc. For: Mar 18 Filed by: Fleming Michael March 28, 2019 4:45 PM - SEC Filing Form 4 Merck & Co., Inc. For: Mar 25 Filed by: Davis Robert M March 27, 2019 5:46 PM - SEC Filing Merck (MRK) CEO Ken Frazier Hinted He Could Step Down - Business Insider March 26, 2019 10:32 AM - StreetInsider NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Closes First Tranche of Private Placement; Plans to Release Early Efficacy Data of Lead Candidate in Combination Study March 26, 2019 10:10 AM - StreetInsider BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting March 26, 2019 6:30 AM - Globe NewsWire S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion March 25, 2019 10:53 AM - PR NewsWire Full Article List